Alumis (NASDAQ:ALMS – Get Free Report) had its target price lowered by Oppenheimer to $28.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer‘s target price would suggest a potential upside of 426.71% from the stock’s current price.
A number of other equities research analysts have also recently commented on ALMS. Benchmark reissued a “buy” rating on shares of Alumis in a research note on Monday, October 5th. Robert W. Baird set a $27.00 price target on Alumis in a report on Tuesday, September 1st. Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Morgan Stanley dropped their price target on shares of Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Finally, HC Wainwright cut their price objective on shares of Alumis from $15.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $31.27.
Check Out Our Latest Research Report on Alumis
Alumis Stock Down 5.1%
Shares of ALMS opened at $5.32 on Monday. The business’s 50 day moving average price is $7.24 and its 200-day moving average price is $20.46. Alumis has a 52 week low of $5.44 and a 52 week high of $31.35. The stock has a market cap of $688.08 million, a P/E ratio of -1.50 and a beta of -0.28.
Alumis (NASDAQ:ALMS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $1.90 million. Alumis had a negative return on equity of 89.77% and a negative net margin of 5,844.54%. On average, equities analysts anticipate that Alumis will post -2.95 EPS for the current year.
Insider Buying and Selling
In other Alumis news, Director Srinivas Akkaraju sold 96,131 shares of Alumis stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the sale, the director owned 2,025,493 shares of the company’s stock, valued at approximately $21,368,951.15. This trade represents a 4.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 99,754 shares of company stock worth $1,037,804. Company insiders own 33.70% of the company’s stock.
Institutional Investors Weigh In On Alumis
Several institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Alumis during the 2nd quarter valued at about $231,259,000. venBio Partners LLC purchased a new stake in shares of Alumis during the 2nd quarter valued at about $127,429,401. Jupiter Topco LLC bought a new stake in shares of Alumis in the second quarter worth approximately $66,238,000. Janus Henderson Group PLC bought a new stake in shares of Alumis in the first quarter worth approximately $46,790,000. Finally, Weiss Asset Management LP bought a new stake in shares of Alumis in the first quarter worth approximately $24,176,000.
Alumis Company Profile
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
Recommended Stories
- Five stocks we like better than Alumis
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
